newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

ARTV
  • Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) priced an underwritten offering of 23,871,526 common shares at $11.52 per share.
  • The company also issued pre-funded warrants to purchase 2,170,138 shares at $11.5199 per share in lieu of common stock for certain investors.
  • Gross proceeds from the offering are expected to be approximately $300 million before deducting underwriting discounts, commissions, and other expenses.
  • The offering is expected to close on or about May 11, 2026, subject to customary closing conditions.
  • Participating investors included Caligan Partners, Venrock Healthcare Capital Partners, Adage Capital Partners, RA Capital Management, Viking Global Management, Samsara BioCapital, EcoR1 Capital, Blackstone Multi-Asset Investing, GC Corporation, GC Cell, RTW Investments, Blue Owl Healthcare Opportunities, and a Large Mutual Fund.
  • Jefferies, TD Cowen, and Cantor served as joint book-running managers, while Wedbush PacGrow and Needham & Company acted as co-lead managers.
  • The securities were offered pursuant to a Form S-3 shelf registration statement declared effective on August 15, 2025.
  • Artiva's lead program, AlloNK (AB-101), is currently in three clinical trials for B-cell driven autoimmune diseases, with a Phase 3 registrational trial for refractory rheumatoid arthritis planned for initiation in 2026.
  • Artiva was founded in 2019 as a spin-out from GC Cell and is headquartered in San Diego, California.